Obseva SA (NASDAQ:OBSV) fell 4%despite announcing that the US FDA had accepted its NDA for linzagolix for heavy menses bleeding management related to uterine fibroids in women nearing menopause. Market Stats On Monday, OBSV stock fell 3.88% at $2.23 with more than 6.97 million shares, compared to its average volume of 699k shares. The stock …
Continue reading “Obseva SA (NASDAQ:OBSV) Stock Ends Lower In A Volatile Session After The News”
Biopharmaceutical company focusing on improving women’s health, ObsEva SA (NASDAQ:OBSV) and Organon , a global women’s health company on July 27, 2021 entered into an agreement. This will entail Organonlicensing the global development, manufacturing as well as commercial rights of ebopiprant (OBE022). Ebopiprant, an investigational, orally active and selective prostaglandin receptor antagonist, is being assessed …
Continue reading “ObsEva SA (NASDAQ:OBSV) Stock Turns Volatile After The News: But Why?”
